Deep Intelligent Pharma Secures $50M Series D to Expand AI-Powered Clinical Documentation Platform
核心洞察
Deep Intelligent Pharma (搜索) (DIP) raised nearly $50 million in Series D funding led by Dinghui Baifu to expand its generative AI platform for pharmaceutical R&D.
The Beijing-based company serves over 1,000 pharma and biotech clients including Johnson & Johnson and Bayer, focusing on streamlining clinical and regulatory document creation.
DIP's multi-agent AI platform targets expensive and error-prone challenges in pharma R&D through intelligent automation of scientific writing, statistical reasoning, and regulatory compliance.
Deep Intelligent Pharma (搜索) (DIP), a Beijing-headquartered generative AI startup serving the pharmaceutical industry, has secured nearly $50 million in Series D funding to accelerate global expansion of its clinical documentation platform. The round was led by Dinghui Baifu, the deeptech-focused investment arm of China's CDH Investments (搜索), with participation from existing investors Xin Ding Capital (搜索) and HongShan Capital Group (搜索).
Addressing Critical R&D Bottlenecks
Founded in 2017, DIP has built a next-generation platform of multi-agent swarms based on generative AI models that serves over 1,000 pharma and biotech clients, including major players Johnson & Johnson and Bayer AG. The company's multi-agent AI platform empowers pharmaceutical and medtech innovators through intelligent automation to streamline scientific writing, statistical reasoning, document validation, and regulatory compliance.
The platform specifically targets one of the most expensive, time-consuming, and error-prone challenges in pharma R&D: the creation of clinical and regulatory documents. This focus addresses a critical bottleneck that has historically slowed drug development timelines and increased costs across the industry.
Strategic Global Expansion Plans
The Series D financing will enable DIP to fund the global expansion of its business and the R&D and upgrade of its AI solutions aimed at improving clinical trial workflows. The startup plans to actively promote the adoption of its AI platform globally, particularly among going-global pharma and biotech companies from China, as more of them step up their global forays with new drug registrations, clinical trials, and collaborations with foreign players across different markets.
DIP expects its number of clients and client orders to "grow exponentially," potentially generating "a few billions of Chinese yuan" in revenues this year, reflecting the strong market demand for AI-powered solutions in pharmaceutical R&D.
Industry Recognition and Competitive Positioning
"What DIP has done is the creation of not just one handy AI tool but a systematic platform targeting the high-barrier and heavily-regulated industry of new drug R&D," said Zhang Chi, Chairman of Xin Ding Capital (搜索). "The team's years of industry know-how and expertise in AI agentic technologies have formed an extremely high bar to fence off competition."
Zhang emphasized that leveraging AI to build the tech infrastructure for global pharma R&D makes the best example of AI's sectoral applications, highlighting the strategic importance of DIP's approach in the broader context of artificial intelligence adoption in healthcare.
Investment History and Market Position
DIP is also backed by venture investors like ZhenFund (搜索), with HongShan Capital Group (搜索) having previously invested nearly $15 million in the company's Series B round in October 2018. Chinese investment bank Index Capital (搜索) served as the financial adviser for the current Series D round, demonstrating continued investor confidence in the company's growth trajectory and market position in the AI-powered pharmaceutical R&D sector.